Benjamin Hohl, CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc. (ELVN), sold 6,018 shares at $42.78 ($264K) on 2026-06-17, disclosed to the SEC on 2026-06-22.
Scheduled sale ($264k) by CHIEF FINANCIAL OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.78 | 1,379 | $59K | 22.4% |
| 2 | $43.86 | 3,401 | $149K | 56.6% |
| 3 | $44.75 | 1,238 | $55K | 21.0% |
| Total | $43.80 avg | 6,018 | $264K | 100% |
| Filing → |
| ELVN | SELL | 2026-07-21 | $317K | — | Filing → |
| ELVN | SELL | 2026-03-10 | $296K | — | Filing → |
| ELVN | SELL | 2025-10-01 | $66K | — | Filing → |